Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05928585 | A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers | PHASE1 | COMPLETED | 30 | — | — | Jul 6, 2023 | Jun 10, 2024 | Feb 7, 2025 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| MAD HIB210 | EXPERIMENTAL | Increasing doses of HIB210 will be administered for cohorts 1-4 in a multiple ascending dose format |
| MAD Placebo | PLACEBO_COMPARATOR | Placebo will be administered for cohorts 1-4 in a multiple ascending dose format |
| Name | Type | Description |
|---|---|---|
| HIB210 | DRUG | Experimental monoclonal antibody |
| Placebo | DRUG | Placebo |
Key Eligibility Criteria: * Healthy male and females between 19 to 65 years of age * Normal or not significantly abnormal laboratory tests and EKG findings during Screening * No significant medical conditions that might affect ability to participate in the study or present a safety risk * No eviden...